Trial intelligence / Profile preview

BCD-148 (Elizaria) vs Soliris in PNH

NCT04060264Phase 3Completed

Sponsor
BIOCAD
Start
Apr 2019
Primary completion
Apr 2020
Modality
Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
Countries
1
01

Overview

A Phase 3 trial of BCD-148 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BIOCAD. Started Apr 2019; status: completed.

02

Drugs

BCD-148
03

Conditions

paroxysmal nocturnal hemoglobinuria (PNH)

Beyond the preview

Go deeper on NCT04060264.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04060264.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call